Belantamab mafodotin for treating relapsed or refractory multiple myeloma

Belantamab mafodotin is in clinical development for the treatment of relapsed and refractory multiple myeloma (MM) patients. MM is a rare form of cancer characterized by excessive production (proliferation) and improper function of certain cells (plasma cells) found in the bone marrow. Myeloma develops due to DNA changes during the development of the plasma cell, producing an abnormal cell that begins to proliferate and produce more cancerous cells. Patients with MM often go through many cycles of treatment options to improve overall survival, which can sometimes lead to poor survival outcomes for patients whose disease has become resistant to the currently available therapy options.